Pharmacodynamics of B-Cell Depletion and Pharmacokinetics of the Novel Anti-CD20 Monoclonal Antibody Ublituximab in Patients With Relapsing Multiple Sclerosis

被引：0

作者：

Fox, E. ^{[1
]}

Steinman, L. ^{[2
]}

Hartung, H. ^{[3
,4
,5
,6
]}

Alvarez, E. ^{[7
]}

Qian, P. ^{[8
]}

Wray, S. ^{[9
]}

Robertson, D. ^{[10
]}

Huang, D. ^{[11
]}

Selmaj, K. ^{[12
]}

Wynn, D. ^{[13
]}

Weiss, M. S. ^{[14
]}

Bosco, J. A. ^{[14
]}

Power, S. A. ^{[14
]}

Mok, K. A. ^{[14
]}

Lee, L. ^{[14
]}

Cree, B. A. ^{[15
]}

机构：

[1] Cent Texas Neurol Consultants, Round Rock, TX USA

[2] Stanford Univ, Stanford, CA 94305 USA

[3] Heinrich Heine Univ, Dusseldorf, Germany

[4] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[5] Med Univ Vienna, Vienna, Austria

[6] Palacky Univ, Olomouc, Czech Republic

[7] Univ Colorado, Aurora, CO USA

[8] Swedish Med Ctr, Seattle, WA USA

[9] Hope Neurol, Knoxville, TN USA

[10] Univ S Florida, Tampa, FL 33620 USA

[11] Mt Carmel Hlth Syst, Ctr Multiple Sclerosis, Westerville, OH USA

[12] Univ Warmia & Mazury, Ctr Neurol, Lodz, Poland

[13] Consultants Neurol, Northbrook, IL USA

[14] TG Therapeut Inc, New York, NY USA

[15] Univ Calif San Francisco, UCSF Weill Inst Neurosci, San Francisco, CA 94143 USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P105

引用

页码：68 / 68

页数：1

共 50 条

[1] A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis
Fox, Edward
Lovett-Racke, Amy E.
Gormley, Matthew
Liu, Yue
Petracca, Maria
Cocozza, Sirio
Shubin, Richard
Wray, Sibyl
Weiss, Michael S.
Bosco, Jenna A.
Power, Sean A.
Mok, Koby
Inglese, Matilde
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (03) : 420 - 429
[2] Rapid and robust B-cell depletion in preliminary results of phase 2 multicenter study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal Antibody (mAb), in patients with relapsing forms of multiple sclerosis (RMS)
Lovett-Racke, A.
Liu, Y.
Racke, M.
Wray, S.
Shubin, R.
Su, W.
Eubanks, J.
Fox, E. J.
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 511 - 511
[3] Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion
Lovett-Racke, Amy
Liu, Yue
Racke, Michael
Shubin, Richard
Wray, Sibyl
Su, Wendy
Eubanks, James
Fox, Edward
NEUROLOGY, 2017, 88
[4] Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis
Roach, Charles A.
Cross, Anne H.
FRONTIERS IN NEUROLOGY, 2021, 11
[5] 6 Month Results of a Phase 2a Multicenter Study of Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Relapsing Multiple Sclerosis
Fox, Edward J.
Lovett-Racke, Amy
Wray, Sibyl
Racke, Michael K.
Shubin, Richard
Twyman, Cary
Eubanks, James
Su, Wendy
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 23 - 23
[6] B-cell depletion in patients with multiple myeloma with the anti-CD20 monoclonal antibody rituximab after high dose therapy
Witzens, M
Gemmel, C
Moos, M
Goldschmidt, H
Ho, AD
BONE MARROW TRANSPLANTATION, 1999, 23 : S141 - S141
[7] Ofatumumab, a Novel Anti-CD20 Monoclonal Antibody for the Treatment of B-Cell Malignancies
Cheson, Bruce D.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (21) : 3525 - 3530
[8] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Finn Sellebjerg
Morten Blinkenberg
Per Soelberg Sorensen
CNS Drugs, 2020, 34 : 269 - 280
[9] Baseline Demographics and Disease Characteristics from the ULTIMATE Phase III Trials Evaluating Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis
Steinman, Lawrence
Fox, Edward
Hartung, Hans-Peter
Cree, Bruce
Alvarez, Enrique
Qian, Peiqing
Wray, Sibyl
Robertson, Derrick
Huang, Deren
Selmaj, Krzystof
Wynn, Daniel
Weiss, Michael
Bosco, Jenna
Power, Sean
Mok, Koby
NEUROLOGY, 2020, 94 (15)
[10] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
Sellebjerg, Finn
Blinkenberg, Morten
Sorensen, Per Soelberg
CNS DRUGS, 2020, 34 (03) : 269 - 280

← 1 2 3 4 5 →